Tirzepatide vs Semaglutide vs Retatrutide Three incretin-class compounds dominate the conversation: tirzepatide (dual GIP/GLP-1), semaglutide (GLP-1 only, sold as Ozempic and Wegovy), and retatrutide (triple agonist GLP-1 + GIP + glucagon, still investigational)
Understanding how these agents work independently is essential before considering their combined use, particularly given that gastrointestinal side effects are among the most common adverse reactions reported with tirzepatide therapy
Meanwhile, those who continued tirzepatide lost an additional 5.5%
OASIS 2: A 68-week efficacy and safety phase 3a trial comparing once-daily oral semaglutide (50 mg) to placebo for weight loss in 198 East Asian (including Japanese) adults with obesity or overweight with one or more comorbidities
Beyond nutrient adequacy, the physical and compositional properties of food significantly influence GI tolerance during semaglutide therapy